Dyne Therapeutics Return on Assets (ROA) Growth & History (DYN)
Dyne Therapeutics's return on assets (roa) was −47.52% for fiscal 2025.
View full Dyne Therapeutics company overviewDyne Therapeutics annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −47.52% | +26.62 pp |
| 2024 | 2024-12-31 | −74.14% | +25.96 pp |
| 2023 | 2023-12-31 | −100.10% | −54.17 pp |
| 2022 | 2022-12-31 | −45.93% | −7.60 pp |
| 2021 | 2021-12-31 | −38.33% | −6.18 pp |
| 2020 | 2020-12-31 | −32.15% | — |
Dyne Therapeutics quarterly return on assets (roa)
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −60.29% | −7.18 pp |
| Q1 2026 | 2026-03-31 | −50.16% | +8.89 pp |
| Q4 2025 | 2025-12-31 | −47.52% | +26.62 pp |
| Q3 2025 | 2025-09-30 | −51.81% | +8.66 pp |
| Q2 2025 | 2025-06-30 | −53.11% | −5.29 pp |
| Q1 2025 | 2025-03-31 | −59.05% | +4.43 pp |
| Q4 2024 | 2024-12-31 | −74.14% | +25.96 pp |
| Q3 2024 | 2024-09-30 | −60.47% | +21.97 pp |
| Q2 2024 | 2024-06-30 | −47.82% | +16.19 pp |
| Q1 2024 | 2024-03-31 | −63.48% | −11.24 pp |
| Q4 2023 | 2023-12-31 | −100.10% | −54.17 pp |
| Q3 2023 | 2023-09-30 | −82.44% | −35.20 pp |
| Q2 2023 | 2023-06-30 | −64.01% | −18.85 pp |
| Q1 2023 | 2023-03-31 | −52.25% | −15.88 pp |
| Q4 2022 | 2022-12-31 | −45.93% | −7.60 pp |
| Q3 2022 | 2022-09-30 | −47.24% | −17.50 pp |
| Q2 2022 | 2022-06-30 | −45.16% | −4.84 pp |
| Q1 2022 | 2022-03-31 | −36.36% | — |
| Q4 2021 | 2021-12-31 | −38.33% | — |
| Q3 2021 | 2021-09-30 | −29.74% | — |
| Q2 2021 | 2021-06-30 | −40.32% | — |
Dyne Therapeutics return on assets (roa) trends
Over the last five fiscal years, Dyne Therapeutics's return on assets (roa) decreased from −32.15% to −47.52%, a change of −15.37 percentage points. The latest reported quarter, Q2 2026, shows −60.29%.
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dyne Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...